Madison, The | |
161 Bakers Ridge Road, Morgantown, West Virginia 26508 | |
(304) 285-0692 | |
Name | Madison, The |
---|---|
Location | 161 Bakers Ridge Road, Morgantown, West Virginia |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 62 |
Occupancy Rate | 67.9% |
Medicare ID (CCN) | 515104 |
Legal Business Name | 161 Bakers Ridge Road Operations Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1073797387 |
Organization Name | 161 BAKERS RIDGE ROAD OPERATIONS LLC |
Doing Business As | MADISON CENTER |
Address | 161 Bakers Ridge Rd, Morgantown, WV 26508 |
Phone Number | 304-285-0692 |
News Archive
More focus should be placed on relieving the most bothersome or "core" symptom for patients with benign prostatic hyperplasia, report Korean researchers.
Go Healthy Natural, a leader in liquid daily dose multivitamins, has announced the launch of their new line of "Antioxidant Boost" liquid multivitamins. The two ounce daily dose liquid multivitamins will be sold in cases of 24 bottles with free shipping and be featured on www.GoHealthyNatural.com and www.Amazon.com.
Antares Pharma, Inc. today announced that its license partner, Ferring Pharmaceuticals has received additional regulatory approvals in Europe and Australia for use of Antares' needle-free injection devices with its human growth hormone (hGH), Zomacton.
Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration.
Enzon Pharmaceuticals, Inc. today announced the Investigational New Drug (IND) approval by the US Food and Drug Administration (FDA) and plan to commence enrollment into a Phase 1a/1b study shortly. The study will evaluate the safety and tolerability of EZN-4176, the company's novel androgen receptor (AR) mRNA antagonist, for the treatment of patients with castration-resistant prostate cancer (CRPC).
› Verified 9 days ago
NPI Number | 1730120486 |
Organization Name | GMA-MADISON INC |
Doing Business As | MADISON REHABILITATION AND NURSING CENTER |
Address | 161 Bakers Ridge Rd, Morgantown, WV 26508 |
Phone Number | 304-285-0692 |
News Archive
More focus should be placed on relieving the most bothersome or "core" symptom for patients with benign prostatic hyperplasia, report Korean researchers.
Go Healthy Natural, a leader in liquid daily dose multivitamins, has announced the launch of their new line of "Antioxidant Boost" liquid multivitamins. The two ounce daily dose liquid multivitamins will be sold in cases of 24 bottles with free shipping and be featured on www.GoHealthyNatural.com and www.Amazon.com.
Antares Pharma, Inc. today announced that its license partner, Ferring Pharmaceuticals has received additional regulatory approvals in Europe and Australia for use of Antares' needle-free injection devices with its human growth hormone (hGH), Zomacton.
Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration.
Enzon Pharmaceuticals, Inc. today announced the Investigational New Drug (IND) approval by the US Food and Drug Administration (FDA) and plan to commence enrollment into a Phase 1a/1b study shortly. The study will evaluate the safety and tolerability of EZN-4176, the company's novel androgen receptor (AR) mRNA antagonist, for the treatment of patients with castration-resistant prostate cancer (CRPC).
› Verified 9 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
More focus should be placed on relieving the most bothersome or "core" symptom for patients with benign prostatic hyperplasia, report Korean researchers.
Go Healthy Natural, a leader in liquid daily dose multivitamins, has announced the launch of their new line of "Antioxidant Boost" liquid multivitamins. The two ounce daily dose liquid multivitamins will be sold in cases of 24 bottles with free shipping and be featured on www.GoHealthyNatural.com and www.Amazon.com.
Antares Pharma, Inc. today announced that its license partner, Ferring Pharmaceuticals has received additional regulatory approvals in Europe and Australia for use of Antares' needle-free injection devices with its human growth hormone (hGH), Zomacton.
Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration.
Enzon Pharmaceuticals, Inc. today announced the Investigational New Drug (IND) approval by the US Food and Drug Administration (FDA) and plan to commence enrollment into a Phase 1a/1b study shortly. The study will evaluate the safety and tolerability of EZN-4176, the company's novel androgen receptor (AR) mRNA antagonist, for the treatment of patients with castration-resistant prostate cancer (CRPC).
› Verified 9 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $9750 |
Number of Payment Denials | 0 |
Total Number of Penalties | 1 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 18.27 | 14.46 |
Percentage of long-stay residents who lose too much weight | 9.52 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 60.53 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 5.83 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 3.23 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 95.16 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 8.26 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 80.56 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 1.51 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 28.35 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 15.24 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 15.29 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.04 | 95.98 |
Percentage of short-stay residents who made improvements in function | 62.65 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 78.65 | 82.93 |
News Archive
More focus should be placed on relieving the most bothersome or "core" symptom for patients with benign prostatic hyperplasia, report Korean researchers.
Go Healthy Natural, a leader in liquid daily dose multivitamins, has announced the launch of their new line of "Antioxidant Boost" liquid multivitamins. The two ounce daily dose liquid multivitamins will be sold in cases of 24 bottles with free shipping and be featured on www.GoHealthyNatural.com and www.Amazon.com.
Antares Pharma, Inc. today announced that its license partner, Ferring Pharmaceuticals has received additional regulatory approvals in Europe and Australia for use of Antares' needle-free injection devices with its human growth hormone (hGH), Zomacton.
Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration.
Enzon Pharmaceuticals, Inc. today announced the Investigational New Drug (IND) approval by the US Food and Drug Administration (FDA) and plan to commence enrollment into a Phase 1a/1b study shortly. The study will evaluate the safety and tolerability of EZN-4176, the company's novel androgen receptor (AR) mRNA antagonist, for the treatment of patients with castration-resistant prostate cancer (CRPC).
› Verified 9 days ago
Morgantown Health And Rehabilitation Center Location: 1379 Van Voorhis Rd, Morgantown, West Virginia 26505 Phone: (304) 599-9480 | |
Stonerise Morgantown Location: 30 Mon General Drive, Morgantown, West Virginia 26505 Phone: (304) 285-2720 | |
Sundale Nursing Home Location: 800 J D Anderson Drive, Morgantown, West Virginia 26505 Phone: (304) 599-0497 | |